## **AMENDMENTS TO THE CLAIMS**

- 1. 112. (Cancelled).
- 113. (Currently Amended) A method for eliciting or enhancing an immune response to HER-2/neu protein in a warm-blooded animal, the method comprising the step of administering to a said warm-blooded animal a composition comprising an isolated protein comprising a HER-2/neu fusion a protein comprising a contiguous amino acid sequence having SEQ ID NO:6 in an amount effective to elicit or enhance the immune response to HER-2/Neu, wherein the HER-2/neu fusion protein comprises an amino acid sequence of SEQ ID NO:6, and wherein the immune response to HER-2/neu fusion protein is capable of producing an immune response in a warm-blooded animal is elicited or enhanced in said animal.
- 114. (Previously presented) The method of claim 113, wherein the composition is administered in the form of a vaccine.
- 115. (Canceled).
- 116. (Currently Amended) A method for eliciting or enhancing an immune response to HER-2/neu protein in a warm-blooded animal, the method comprising the step of administering to a said warm-blooded animal a composition comprising an isolated protein comprising a HER-2/neu fusion a protein comprising a contiguous amino acid sequence having SEQ ID NO:7 in an amount effective to elicit or enhance the immune response to Her-2/Neu, wherein the HER-2/neu fusion protein comprises an amino acid sequence of SEQ ID NO:7, and wherein the immune response to HER-2/neu fusion protein is capable of producing an immune response in a warm blooded animal is elicited or enhanced in said animal.
- 117. (Currently amended) The method of claim 113, wherein the fusion said protein is lipidated.

Application No. 09/854,356 Attorney Docket No. CRX113US1

- 118. (Previously presented) The method of claim 113, wherein the composition comprises a physiologically acceptable carrier or diluent.
- 119. (Previously presented) The method of claim 118, wherein the composition comprises an oil-in-water emulsion.
- 120. (Previously presented) The method of claim 119, wherein the composition comprises tocopherol.
- 121. (Previously presented) The method of claim 113, wherein the composition comprises an immunostimulatory substance.
- 122. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
- 123. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
- 124. (Previously presented) The method of claim 123, wherein the composition comprises tocopherol.
- 125. (Previously presented) The method of claim 113, wherein the composition comprises a CpG-containing oligonucleotide.
- 126-144. (Canceled).
- 145. (Previously presented) The method of claim 116, wherein the composition is administered in the form of a vaccine.

Application No. 09/854,356 Attorney Docket No. CRX113US1

- 146. (Currently amended) The method of claim 116, wherein <u>said</u> the fusion protein is lipidated.
- 147. (Previously presented) The method of claim 116, wherein the composition comprises a physiologically acceptable carrier or diluent.
- 148. (Previously presented) The method of claim 147, wherein the composition comprises an oil-in-water emulsion.
- 149. (Previously presented) The method of claim 148, wherein the composition comprises tocopherol.
- 150. (Previously presented) The method of claim 116, wherein the composition comprises an immunostimulatory substance.
- 151. (Previously presented) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
- 152. (Previously presented) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
- 153. (Previously presented) The method of claim 152, wherein the composition comprises tocopherol.
- 154. (Previously presented) The method of claim 116, wherein the composition comprises a CpG-containing oligonucleotide.
- 155. (New). The method of claim 113 where said warm-blooded animal is a human.

Application No. 09/854,356 Attorney Docket No. CRX113US1

156. (New) The method of claim 116, where said warm-blooded animal is a human.